Info

🌱 來自：Treatment principles-of-renal-cell-carcinoma

carmena trial

• Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma List of authors.

MÉJEAN, Arnaud, et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. New England Journal of Medicine, 2018, 379.5: 417-427.

• The median overall survival was 18.4 months in the sunitinib-alone group and 13.9 months in the nephrectomy-sunitinib group.
• No significant differences in response rate or progression-free survival were observed. Adverse events were as anticipated in each group.